Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
Atrial fibrillation is a major risk factor for stroke, which causes thousands of deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk of stroke use an oral anticoagulant to reduce the risk of stroke. In the past few years, three new oral anticoagulants (NOACs), dabigatran, rivaroxaban, and apixaban, have been introduced in competition to the older oral anticoagulant warfarin.
The objective of this study was to evaluate the relative cost effectiveness of warfarin, dabigatran, rivaroxaban, and apixaban in a Norwegian setting.
We created a probabilistic decision–analytic Markov model to simulate the life of patients with atrial fibrillation. We performed several scenario analyses, including changing the switching age for dabigatran from 80 to 75 years old.
Assuming the European Society of Cardiology guidance, sequential dabigatran (2 × 150 mg daily until 80 years old, 2 × 110 mg thereafter) seems to be the most cost-effective alternative for high-risk AF patients. For medium-risk patients, apixaban (2 × 5 mg daily) seems to be somewhat more effective than dabigatran, but dabigatran is still marginally the most cost-effective alternative. In scenario analyses reducing dabigatran from 2 × 150 mg to 2 × 110 mg at the age of 75 years (instead of at age 80), apixaban (2 × 5 mg daily) becomes the most cost-effective alternative for both risk groups.
We have found apixaban or sequential dabigatran to be the alternatives most likely to be considered cost effective, depending on the switching age for dabigatran. These conclusions are highly sensitive to assumptions made in the analysis.
- Friberg, J, Scharling, H, Gadsboll, N, Truelsen, T, Jensen, GB (2004) Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 94: pp. 889-894 CrossRef
- Camm, AJ, Lip, GY, De, CR, Savelieva, I, Atar, D, Hohnloser, SH (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 14: pp. 1385-1413 CrossRef
- Roger, VL, Go, AS, Lloyd-Jones, DM, Benjamin, EJ, Berry, JD, Borden, WB (2012) Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 125: pp. e2-e220 CrossRef
- Rivero-Ayerza, M, Scholte Op, RW, Lenzen, M, Theuns, DA, Jordaens, L, Komajda, M (2008) New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J 29: pp. 1618-1624 CrossRef
- Singer, DE, Albers, GW, Dalen, JE, Fang, MC, Go, AS, Halperin, JL (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133: pp. 546S-592S CrossRef
- Camm, AJ, Kirchhof, P, Lip, GY, Schotten, U, Savelieva, I, Ernst, S (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31: pp. 2369-2429 CrossRef
- You, JJ, Singer, DE, Howard, PA, Lane, DA, Eckman, MH, Fang, MC (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141: pp. e531S-e575S
- Limone, BL, Baker, WL, Kluger, J, Coleman, CI (2013) Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One 8: pp. e62183 CrossRef
- Caro, JJ, Briggs, AH, Siebert, U, Kuntz, KM (2012) Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making 32: pp. 667-677 CrossRef
- Coyle, D, Coyle, K, Cameron, C, Lee, K, Kelly, S, Steiner, S (2013) Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health 16: pp. 498-506 CrossRef
- Harrington, AR, Armstrong, EP, Nolan, PE, Malone, DC (2013) Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 44: pp. 1676-1681 CrossRef
- Lip, GY, Nieuwlaat, R, Pisters, R, Lane, DA, Crijns, HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 137: pp. 263-272 CrossRef
- Pisters, R, Lane, DA, Nieuwlaat, R, Vos, CB, Crijns, HJ, Lip, GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138: pp. 1093-1100 CrossRef
- Friberg, L, Rosenqvist, M, Lip, GY (2012) Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J 33: pp. 1500-1510 CrossRef
- Olesen, JB, Lip, GY, Hansen, ML, Hansen, PR, Tolstrup, JS, Lindhardsen, J (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342: pp. d124 CrossRef
- Harmsen, P, Wilhelmsen, L, Jacobsson, A (2009) Stroke incidence and mortality rates 1987 to 2006 related to secular trends of cardiovascular risk factors in Gothenburg, Sweden. Stroke 40: pp. 2691-2697 CrossRef
- Hansen, ML, Sorensen, R, Clausen, MT, Fog-Petersen, ML, Raunso, J, Gadsboll, N (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170: pp. 1433-1441 CrossRef
- Olesen, JB, Lip, GY, Lindhardsen, J, Lane, DA, Ahlehoff, O, Hansen, ML (2011) Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 106: pp. 739-749 CrossRef
- Øyen, N, Nygård, O, Igland, J, Tell, GS, Nordrehaug, JE, Irgens, LM (2008) Hospital admission rates for cardiovascular diseases in Western Norway, 1992–2001 [in Norwegian]. Tidsskr Nor Laegeforen 128: pp. 17-23
- Henriksson, KM, Farahmand, B, Johansson, S, Asberg, S, Terent, A, Edvardsson, N (2010) Survival after stroke—the impact of CHADS2 score and atrial fibrillation. Int J Cardiol 141: pp. 18-23 CrossRef
- Shafazand, M, Rosengren, A, Lappas, G, Swedberg, K, Schaufelberger, M (2011) Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993–2004: a study of 175,216 patients with a first acute myocardial infarction in Sweden. Eur J Heart Fail 13: pp. 135-141 CrossRef
- Tveit, A, Flonaes, B, Aaser, E, Korneliussen, K, Froland, G, Gullestad, L (2011) No impact of atrial fibrillation on mortality risk in optimally treated heart failure patients. Clin Cardiol 34: pp. 537-542 CrossRef
- Riks-Stroke. Yearly report 2010 [in Swedish]. http://www.riks-stroke.org/content/analyser/Riks-Stroke_%C3%85rsrapport2010.pdf (2011). Accessed 22 Mar 2014.
- Olesen, JB, Lip, GY, Hansen, PR, Lindhardsen, J, Ahlehoff, O, Andersson, C (2011) Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 9: pp. 1460-1467 CrossRef
- Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156(5):855–63, 863.e2.
- Hillen, T, Coshall, C, Tilling, K, Rudd, AG, McGovern, R, Wolfe, CD (2003) Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 34: pp. 1457-1463 CrossRef
- Caro, JJ, Migliaccio-Walle, K, Ishak, KJ, Proskorovsky, I, O’Brien, JA (2006) The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada. BMC Health Serv Res 6: pp. 99 CrossRef
- Mosterd, A, Cost, B, Hoes, AW, Bruijne, MC, Deckers, JW, Hofman, A (2001) The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 22: pp. 1318-1327 CrossRef
- Cleland, JG, Swedberg, K, Follath, F, Komajda, M, Cohen-Solal, A, Aguilar, JC (2003) The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24: pp. 442-463 CrossRef
- Banerjee, A, Lane, DA, Torp-Pedersen, C, Lip, GY (2012) Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 107: pp. 584-589 CrossRef
- Henriksson, KM, Andersson, T, Magnusson, A, Bryngelsson, I-L, Frobert, O, Edvardsson, N (2011) A cohort study of all-cause mortality in all patients with a first time hospitalization with atrial fibrillation, versus matched controls, In Sweden during 15 years, 1995–2009 [conference abstract]. Pharmacoepidemiol Drug Saf 20: pp. S22-S23
- Connolly, SJ, Ezekowitz, MD, Yusuf, S, Eikelboom, J, Oldgren, J, Parekh, A (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: pp. 1139-1151 CrossRef
- Patel, MR, Mahaffey, KW, Garg, J, Pan, G, Singer, DE, Hacke, W (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: pp. 883-891 CrossRef
- Granger, CB, Alexander, JH, McMurray, JJ, Lopes, RD, Hylek, EM, Hanna, M (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: pp. 981-992 CrossRef
- Oxman, AD (2012) Subgroup analyses. BMJ 344: pp. e2022 CrossRef
- European Medicines Agency. EPAR summary for the public: pradaxa, dabigatran etexilate (EMA/544606/2012). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000829/WC500041060.pdf. (2012). Accessed 22 Mar 2014.
- Norwegian Medicines Agency. Reimbursement report: dabigatran (Pradaxa) for prevention of stroke and systemic embolism [in Norwegian]. http://www.legemiddelverket.no/Blaa_resept_og_pris/blaaresept_forhaandsgodkjent_refusjon/refusjonsbeslutninger/Documents/2012-2011/Pradaxa_atrieflimmer_2012.pdf (2012). Accessed 22 Mar 2014.
- Wisløff T, Selmer R, Halvorsen S, Kristiansen IS. Norwegian Cardiovascular Disease Model (NorCaD)—a simulation model for estimating health benefits and cost consequences of cardiovascular interventions. 23. 2008. Report from Kunnskapssenteret (Norwegian Knowledge Centre for the Health Services), No. 23-2008. http://www.kunnskapssenteret.no/publikasjoner/_attachment/4128?_ts=11d1a7a8760&download=false. Accessed 22 Mar 2014.
- The Norwegian Directorate of Health. Economic evaluation of health interventions—a guideline [in Norwegian]. http://www.helsedirektoratet.no/publikasjoner/okonomisk-evaluering-av-helsetiltak-en-veileder/Publikasjoner/IS-1985.pdf (2012 IS-1985). Accessed 22 Mar 2014.
- Lunde L. Economic evaluations in the health care market: methodological issues and challenges [PhD thesis]. Bergen: University of Bergen; 2012.
- Berg, J, Lindgren, P, Nieuwlaat, R, Bouin, O, Crijns, H (2010) Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual Life Res 19: pp. 381-390 CrossRef
- Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11(51): iii–iv, 1–164.
- Lee, HY, Hwang, JS, Jeng, JS, Wang, JD (2010) Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke 41: pp. 739-744 CrossRef
- Coleman, CI, Sobieraj, DM, Winkler, S, Cutting, P, Mediouni, M, Alikhanov, S (2012) Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 66: pp. 53-63 CrossRef
- Rasanen, P, Roine, E, Sintonen, H, Semberg-Konttinen, V, Ryynanen, OP, Roine, R (2006) Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care 22: pp. 235-241
- Wisløff T, Hagen G, Hamidi V, Movik E, Klemp M, Olsen JA. Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010. Pharmacoeconomics. Epub 2014 Jan 30. doi:10.1007/s40273-014-0136-z.
- Briggs, AH, Claxton, K, Sculpher, M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
- Altman, DG (1991) Practical statistics for medical research. Chapman & Hall, London
- Thompson, SG, Nixon, RM (2005) How sensitive are cost-effectiveness analyses to choice of parametric distributions?. Med Decis Making 25: pp. 416-423 CrossRef
- Briggs, AH, Claxton, K, Sculpher, M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
- Lainscak, M, Cleland, JG, Lenzen, MJ, Keber, I, Goode, K, Follath, F (2007) Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. Am J Cardiol 99: pp. 31D-37D CrossRef
- Fenwick, E, Claxton, K, Sculpher, M (2001) Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10: pp. 779-787 CrossRef
- Claxton, K, Sculpher, M, McCabe, C, Briggs, A, Akehurst, R, Buxton, M (2005) Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 14: pp. 339-347 CrossRef
- Al, MJ (2013) Cost-effectiveness acceptability curves revisited. Pharmacoeconomics 31: pp. 93-100 CrossRef
- Weinstein, MC, O’Brien, B, Hornberger, J, Jackson, J, Johannesson, M, McCabe, C (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 6: pp. 9-17 CrossRef
- Wallentin, L, Yusuf, S, Ezekowitz, MD, Alings, M, Flather, M, Franzosi, MG (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376: pp. 975-983 CrossRef
- Graff-Iversen, S, Gjesdal, K, Jugessur, A, Myrstad, M, Nystad, W, Selmer, R (2012) Atrial fibrillation, physical activity and endurance training [in English, Norwegian]. Tidsskr Nor Laegeforen 132: pp. 295-299 CrossRef
- Wisløff T, Ringerike T, Hagen G, Reikvam Å, Klemp M. Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation. 2013;5:1–79. http://www.kunnskapssenteret.no/Publikasjoner/_attachment/18119?_ts=13df823146a&download=true. Accessed 22 Mar 2014.
- Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 32, Issue 6 , pp 601-612
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Norwegian Knowledge Centre for the Health Services, Postboks 7004, St. Olavs Plass, 0130, Oslo, Norway
- 2. Department of Biostatistics, Epidemiology and Health Economics, Oslo University Hospital, Oslo, Norway
- 3. Department of Health Management and Health Economics, University of Oslo, Oslo, Norway
- 4. Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway
- 5. Department of Pharmacology, University of Oslo, Oslo, Norway